RexMed attended the National Home Infusion Association, NHIA Conference 2025, in Washington, D.C. The event focused on the growing trend of delivering specialized intravenous treatments directly to patients’ homes. We joined with WalkMed Infusion, an Original Equipment Manufacturer (OEM).
That alliance validates the critical importance of manufacturing precision and demonstrates how strict quality controls directly translate into user trust and product effectiveness.
WalkMed leads the way in safe and reliable ambulatory infusion equipment, and RexMed provides the manufacturing foundation that their cutting-edge products require.
NHIA Conference: The home healthcare imperative
The shift toward home infusion represents a significant evolution in healthcare delivery. It enables patients to manage chronic conditions—such as infections, pain, or certain types of cancer—in a comfortable, non-hospital setting, thereby significantly improving their quality of life.
This paradigm shift, however, places immense pressure on medical device manufacturers. The devices must perform flawlessly in environments outside a highly controlled clinical setting. The NHIA conference was our platform to address these challenges.
In fact, industry leaders and policymakers discussed creating regulatory frameworks for highly reliable equipment. RexMed provides the necessary manufacturing infrastructure, ensuring we successfully meet this vital need in the home healthcare market.
Precision manufacturing as a safety guarantee
WalkMed’s ambulatory pumps, such as the highly portable 350VL model, require precise component manufacturing. Any minor deviation in a moving part or housing component can compromise the pump’s accuracy or its long-term durability.
At our exhibit, we detailed the manufacturing rigor RexMed applies to these critical components. We explained the following implications:
- Advanced materials selection. We use polymers and seals that resist degradation from cleaning agents and body fluids.
- Zero-Defect assembly. We implement validated cleanroom assembly procedures to ensure the integrity of the mechanisms.
Finally, we guarantee comprehensive documentation for every part. This supports WalkMed’s regulatory compliance and patient safety standards.
Advocacy and market growth insights
Beyond manufacturing, the conference provided us with crucial numerical insights. Sessions highlighted the growth potential of the global home infusion market. Reports project that it will exceed $84 billion by 2034.
Regulatory advocacy
We actively investigated the most recent legislative efforts, paying close attention to initiatives like the Preserving Patient Access to Home Infusion Act. These types of legal initiatives seek to improve and standardize Medicare coverage for these essential therapies.
Understanding this legislative landscape is crucial; it enables us to anticipate market shifts and ensure that our clients’ products meet future regulatory requirements. We provide our manufacturing planning aligns with the time these advocacy efforts create.
Payer models
At the NHIA conference, we also analyzed various strategies for managing complex Medicare Part B/D and commercial insurer contracts. We must understand that the primary goal is not just processing claims, but guaranteeing patient access to necessary devices. This focus on access is central to the success of our OEM partners.
At RexMed, we actively show our focus on guiding clients through contract requirements and complex reimbursement landscapes. By staying current on payer demands and documentation needs, we ensure our manufacturing compliance protocols align directly with billing and regulatory requirements.
This integrated approach ensures the devices we manufacture reach the patients who need them without unnecessary financial or administrative hurdles. This process ultimately accelerates market adoption for our clients.
Looking ahead: The future of infusion
The NHIA sessions inform RexMed’s strategic planning, ensuring we scale our manufacturing capacity and compliance protocols. We commit to remaining a strategic partner for leading Original Equipment Manufacturers (OEMs), such as WalkMed Infusion.
Working together, we can not only meet but exceed the demands of this expanding and demanding healthcare frontier. We eliminate all doubt: at RexMed, we are fully prepared to tackle the challenges presented by the next generation of home infusion devices.
Is your company seeking a reliable partner that guarantees the precision and regulatory compliance necessary for success in the home health market? We encourage you to visit our website and learn more about our manufacturing solutions.
